CLX Medical, Inc. Announces New CEO Interview With Questions Regarding Planned Acquisition of the ThyroTest(R) Rapid Screening Device

Marketing Strategy and Action Plan for ThyroTest® Device Discussed in Question and Answer Feature Posted to the Company’s Website

MURRIETA, CA–(EMWNews – August 14, 2008) – CLX Medical, Inc. (OTCBB: CLXN), which is

focused on the launch and distribution of unique medical diagnostic testing

products, today announced that Vera Leonard, chief executive officer of the

company, has participated in a question and answer feature that has been

posted to the CLX website at http://www.clxmedical.com/othermedia.php. The

transcript will also be added to the company’s profile on

www.equitydigest.com in the coming days.

The focus of the interview is the company’s recent announcement that it has

entered into a letter of intent with ThyroTec, LLC to acquire ThyroTest®,

a rapid thyroid stimulating hormone (TSH) screening device used for the

detection of hypothyroidism in adults, a common thyroid disease.

In the interview, Ms. Leonard discusses the reasons that CLX targeted

ThyroTest® for acquisition, the size of the potential market for the

product, the U.S. and worldwide distribution strategy for ThyroTest®, and

the competitive landscape for the product.

Ms. Leonard also provides a summary of the company’s progress since she was

appointed to the position of CEO in 2007.

ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the

test can be administered in the more than 100,000 CLIA waived doctors’

offices in the U.S., as well as in any non-waived laboratory. The simple

rapid diagnostic test is a qualitative measurement that allows physicians

to screen adult patients for hypothyroidism in approximately ten minutes

with a whole blood sample.

Hypothyroidism develops when the thyroid gland does not produce enough

thyroid hormone to properly regulate the body’s metabolism. A lack of

thyroid hormone affects many body systems. The incidence of hypothyroidism

tends to increase with age, with older people, especially women, at highest

risk. Common symptoms include weight gain, fatigue, mood swings, weakness,

dry and coarse skin and hair, hair loss, depression, decreased libido,

trouble swallowing, increased cholesterol, heavy or irregular periods or

trouble getting pregnant.

Approximately 120 million thyroid-related lab tests are performed in the

United States each year. At an estimated average cost of $40 per test, the

U.S. market is currently valued at nearly $5 billion. Approximately 45

million of those tests are conducted in order to diagnose thyroid

dysfunction. CLX believes that ThyroTest® is an appropriate, cost-effective

first-step for those 45 million diagnostic TSH tests. This current U.S.

market opportunity is amplified by the CLIA waived status, which makes the

opportunity to meet American Thyroid Association recommendations for

screening every individual at age 35 and every five years thereafter a

reality.

To sign up to receive information by email directly from CLX Medical, Inc.

when new press releases, investor newsletters, SEC filings, or other

information is disclosed, please visit

http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in

Zonda, Inc. (www.zondaincusa.com), which has developed several rapid point

of care tests for medical and non-medical markets, including a rapid test

for Chlamydia. CLX recently announced a letter of intent to acquire

ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device

used for the detection of hypothyroidism in adults, a common thyroid

disease. CLX Medical is focused on the successful worldwide distribution

of these and any additional products it may acquire or license.

All statements included in this release, including statements regarding

potential future plans and objectives of CLX Medical, Inc. are

forward-looking statements. Such statements are necessarily subject to

risks and uncertainties, some of which are significant in scope and nature

beyond CLX Medical’s control. There can be no assurance that such

statements will prove accurate. Actual results and future events could

differ materially from those anticipated in such statements depending on

many factors. Historical results are not necessarily indicative of future

performance.